Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05144347 · ClinicalTrials.gov registry record · Phase 1
Study of XL114 in Subjects With Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by Exelixis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT05144347 is a Phase 1 study that was terminated before completion, run by Exelixis. The registered enrollment target is 2 participants.
The verdict
NCT05144347, a Phase 1 study, was terminated before completion, sponsored by Exelixis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a Phase 1, non-randomized, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical antitumor activity of XL114 administered alone orally to subjects with Non-Hodgkin's Lymphoma (NHL). The objectives of the study also include determining the recommended dose (RD) and/or maximum tolerated dose (MTD) of XL114.
Interventions
- DRUG XL114
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-04-12 |
| Est. Completion | 2022-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05144347
The ClinicalTrials.gov registry entry for NCT05144347 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which XL114 is the first listed.
NCT05144347 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05144347 about?
NCT05144347 is a clinical study titled "Study of XL114 in Subjects With Non-Hodgkin's Lymphoma". This is a Phase 1, non-randomized, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical antitumor activity of XL114 administered alone orally to subjects with Non-Hodgkin's Lymphoma (NHL). The obj...
What is the current status of trial NCT05144347?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2022-04-12. Estimated completion is 2022-11-01.
What interventions are being tested in trial NCT05144347?
The interventions under investigation include: XL114 (DRUG).
Who is sponsoring clinical trial NCT05144347?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.